Expert Opinion on Therapeutic Patents最新文献_第10页

Therapeutic treatment strategies for the management of onychomycosis: a patent perspective. ONYCHOMCOSIS治疗策略：专利视角。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-07-01 Epub Date: 2023-11-28 DOI: 10.1080/13543776.2023.2268278

Snigdha Chakraborty, Sanshita, Inderbir Singh

{"title":"Therapeutic treatment strategies for the management of onychomycosis: a patent perspective.","authors":"Snigdha Chakraborty, Sanshita, Inderbir Singh","doi":"10.1080/13543776.2023.2268278","DOIUrl":"10.1080/13543776.2023.2268278","url":null,"abstract":"Introduction: Onychomycosis, a multifactorial fungal infection of the nails, shows a global prevalence of about 5.5% and is responsible for 50% of all nail infections. To develop effective management strategies, it is necessary to understand the etiology, pathophysiology, and risk factors of onychomycosis. Oral route of drug delivery is one of the routes utilized to deliver anti-fungal agents, but, has its own limitations like longer duration of treatment, increased adverse effects, and potential for drug interaction. The ungual route has received greater attention due to its localized, non- invasive action and improved patient compliance.Areas covered: This review comprehensively discusses conventional onychomycosis therapies and patented novel drug delivery systems for the management of onychomycosis including chemical permeation enhancers, non-particulate drug delivery systems, penetration enhancing devices etc., Databases such as PubMed, ResearchGate, and Google Patents were searched by using the keywords onychomycosis and trans-ungual drug delivery.Expert opinion: Enormous research has been conducted and is still ongoing to find the best possible novel drug delivery system for onychomycosis management. Approaches like incorporation of herbal constituents in nano-formulations, inkjet printing, laser devices, iontophoretic techniques, etc. can be employed to make safe and effective drug delivery systems which are regulatory compliant.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"613-630"},"PeriodicalIF":6.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41128178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An updated patent review of GLP-1 receptor agonists (2020-present). GLP-1受体激动剂的最新专利综述（2020至今）。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-07-01 Epub Date: 2023-11-28 DOI: 10.1080/13543776.2023.2274905

Weiwen Lu, Zhongbo Zhou, Neng Jiang, Jing Han

{"title":"An updated patent review of GLP-1 receptor agonists (2020-present).","authors":"Weiwen Lu, Zhongbo Zhou, Neng Jiang, Jing Han","doi":"10.1080/13543776.2023.2274905","DOIUrl":"10.1080/13543776.2023.2274905","url":null,"abstract":"Introduction: Type 2 diabetes (T2DM) and obesity present significant global health issues, requiring the development of long-lasting and highly effective pharmacotherapies. Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) are commonly used for diabetes treatment, their potential for addressing obesity is still being explored.Areas covered: This review offers a comprehensive overview of recently published patents from January 2020 to July 2023, focusing on modified GLP-1RAs, small molecule GLP-1RAs, GLP-1 R-based multi-agonists, GLP-1RA-based fusion proteins, and combination therapies. The patents discussed pertain to the treatment and prevention of diabetes and obesity. Patent searches were conducted using the PATENTSCOPE database of the World Intellectual Property Organization, using the keywords GLP-1, GLP-1/GIP, GLP-1/GCG, and GLP-1/GCG/GIP.Expert opinion: In recent years, patents have emphasized two main goals for developing GLP-1RAs drugs: oral delivery and improved weight reduction effects. To address the growing demand for improved treatments, researchers have focused their efforts on developing GLP-1 R-based multi-agonists, orally administered GLP-1RAs, and combination therapies utilizing GLP-1RAs. These new approaches offer promising benefits, such as improved effectiveness by targeting multiple pathways and reduced side effects. Additionally, the development of new uses, oral forms, and long-lasting preparations will be crucial in shaping the future market potential of GLP-1 drugs.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"597-612"},"PeriodicalIF":6.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49689564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An updated patent review of metallo-β-lactamase inhibitors (2020-2023). 金属-β-内酰胺酶抑制剂的最新专利综述（2020-2023）。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-07-01 Epub Date: 2023-11-06 DOI: 10.1080/13543776.2023.2262763

Elsa Denakpo, Thierry Naas, Bogdan I Iorga

{"title":"An updated patent review of metallo-β-lactamase inhibitors (2020-2023).","authors":"Elsa Denakpo, Thierry Naas, Bogdan I Iorga","doi":"10.1080/13543776.2023.2262763","DOIUrl":"10.1080/13543776.2023.2262763","url":null,"abstract":"Introduction: Metallo-β-lactamases (MBLs) are enzymes produced by bacteria that confer resistance to most β-lactam antibiotics, including carbapenems, which have the broadest spectrum of activity. This resistance mechanism poses a significant threat to public health as it drastically reduces treatment options for severe bacterial infections. Developing effective inhibitors against MBLs is crucial to restore susceptibility to β-lactam antibiotics.Areas covered: This review aims to provide an updated analysis of patents describing novel MBL inhibitors and their potential therapeutic applications that were filed between January 2020 and May 2023.Expert opinion: Significant advancements were made in the development of selective MBL inhibitors with zinc-binding and zinc-chelating mechanisms of action. Dual inhibitors, targeting simultaneously both serine-β-lactamases (SBLs) and MBLs, represent an interesting alternative approach that is increasingly pertinent for the treatment of infections involving multiple β-lactamases from different Ambler classes. Most examples of MBL-specific inhibitors were focused on the treatment of MBL-mediated infections in Enterobacterales, where IMP-1 was a more difficult target compared with VIM-1 or NDM-1, and much less on Pseudomonas aeruginosa or Acinetobacter baumannii, which are more challenging to address.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"523-538"},"PeriodicalIF":6.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41119008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances on patents of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors as antimalarial agents. 恶性疟原虫二氢乳清酸脱氢酶（PfDHODH）抑制剂作为抗疟药物专利的最新进展。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-07-01 Epub Date: 2023-11-28 DOI: 10.1080/13543776.2023.2280596

Pinky Gehlot, Vivek K Vyas

{"title":"Recent advances on patents of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors as antimalarial agents.","authors":"Pinky Gehlot, Vivek K Vyas","doi":"10.1080/13543776.2023.2280596","DOIUrl":"10.1080/13543776.2023.2280596","url":null,"abstract":"Introduction: Pyrimidine nucleotides are essential for the parasite's growth and replication. Parasites have only a de novo pathway for the biosynthesis of pyrimidine nucleotides. Dihydroorotate dehydrogenase (DHODH) enzyme is involved in the rate-limiting step of the pyrimidine biosynthesis pathway. DHODH is a biochemical target for the discovery of new antimalarial agents.Area covered: This review discussed the development of patented PfDHODH inhibitors published between 2007 and 2023 along with their chemical structures and activities.Expert opinion: PfDHODH enzyme is involved in the rate-limiting fourth step of the pyrimidine biosynthesis pathway. Thus, inhibition of PfDHODH using species-selective inhibitors has drawn much attention for treating malaria because they inhibit parasite growth without affecting normal human functions. Looking at the current scenario of antimalarial drug resistance with most of the available antimalarial drugs, there is a huge need for targeted newer agents. Newer agents with unique mechanisms of action may be devoid of drug toxicity, adverse effects, and the ability of parasites to quickly gain resistance, and PfDHODH inhibitors can be those newer agents. Many PfDHODH inhibitors were patented in the past, and the dependency of Plasmodium on de novo pyrimidine provided a new approach for the development of novel antimalarial agents.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"579-596"},"PeriodicalIF":6.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71521002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Conjugates of monocyclic β-lactams and siderophore mimetics: a patent evaluation (WO2023023393). 单环β-内酰胺和铁载体模拟物的缀合物：专利评估（WO2023023393）。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-07-01 Epub Date: 2023-11-06 DOI: 10.1080/13543776.2023.2262135

Alen Krajnc, Stanislav Gobec

{"title":"Conjugates of monocyclic β-lactams and siderophore mimetics: a patent evaluation (WO2023023393).","authors":"Alen Krajnc, Stanislav Gobec","doi":"10.1080/13543776.2023.2262135","DOIUrl":"10.1080/13543776.2023.2262135","url":null,"abstract":"Introduction: β-Lactams, which include monobactams, remain the most important class of antibiotics worldwide. Aztreonam, the only monobactam in clinical use, has remarkable activity against many Gram-negative bacteria, but limited activity against some of the most problematic multidrug-resistant (MDR) pathogens, such as MDR Pseudomonas aeruginosa and Acinetobacter baumannii co-expressing extended-spectrum- and metallo-β-lactamases, which can inactivate aztreonam by hydrolysis.Areas covered: Structurally novel siderophore-conjugated aztreonam derivatives with improved antibacterial properties against several high-priority pathogens are claimed. This invention reports that sidechain extension of aztreonam is tolerated; the coupling of its aminothiazoloxime carboxylic acid part with a siderophore mimetic significantly improved the antibacterial activity against several problematic strains, including MDR A. baumannii isolates with carbapenemase/cephalosporinase activity.Expert opinion: Finding new strategies to tackle bacterial resistance to β-lactam antibiotics is critical. Considering that β lactams are validated and safe drugs, this research may stimulate the field to develop new ideas in the arena of antimicrobial drug discovery, particularly with respect to siderophore mimetics.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"471-476"},"PeriodicalIF":6.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71411304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CDC7 kinase inhibitors: a survey of recent patent literature (2017-2022). CDC7激酶抑制剂：近期专利文献综述（2017-2022）。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-07-01 Epub Date: 2023-11-06 DOI: 10.1080/13543776.2023.2262138

Takayuki Irie, Masaaki Sawa

{"title":"CDC7 kinase inhibitors: a survey of recent patent literature (2017-2022).","authors":"Takayuki Irie, Masaaki Sawa","doi":"10.1080/13543776.2023.2262138","DOIUrl":"10.1080/13543776.2023.2262138","url":null,"abstract":"Introduction: CDC7 is a serine/threonine kinase which plays an important role in DNA replication. Inhibition of CDC7 in cancer cells causes lethal S phase or M phase progression, whereas inhibition of CDC7 in normal cells does not cause cell death and only leads to cell cycle arrest at the DNA replication checkpoint. Therefore, CDC7 has been recognized as a potential target for novel therapeutic interventions in cancers.Areas covered: Patent literature claiming novel small molecule compounds inhibiting CDC7 disclosed from 2017 to 2022.Expert opinion: Despite the indisputable positive impact of CDC7 as a drug target, there have been reported only a handful of chemical scaffolds as CDC7 inhibitors. Several CDC7 inhibitors have been progressed into clinical trials for cancer treatments, but they did not result in satisfactory efficacies in those trials. One possible reason for the failure might be due to the dose-limiting toxicities, and some of the observed toxicities were thought to be not related to CDC7 inhibition, suggesting it should be important to identify novel chemical scaffolds to eliminate unwanted toxicities. Another important factor is the patient stratification that would enable greater response, and the identification of such predictive biomarkers should be the key to success for the development of CDC7 inhibitors.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"493-501"},"PeriodicalIF":6.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41112843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An updated patent review of GPR40/ FFAR1 modulators (2020 - present). GPR40/FFAR1调制器的最新专利审查（2020年至今）。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-07-01 Epub Date: 2023-11-28 DOI: 10.1080/13543776.2023.2272649

Qiang Ren, Yiqing Fan, Lixin Yang, Mayu Shan, Wei Shi, Hai Qian

引用次数: 0

The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders. 下一代EGFR抑制剂：基于PROTACs的EGFR降解剂的专利前景。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-07-01 Epub Date: 2023-11-06 DOI: 10.1080/13543776.2023.2262176

Pengyun Li, Bingkun Li, Ning Yang, Tingting Xu, Zhibing Zheng

{"title":"The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders.","authors":"Pengyun Li, Bingkun Li, Ning Yang, Tingting Xu, Zhibing Zheng","doi":"10.1080/13543776.2023.2262176","DOIUrl":"10.1080/13543776.2023.2262176","url":null,"abstract":"Introduction: Abnormal expression of epidermal growth factor receptor (EGFR) contributes to tumor development, especially in non-small cell lung cancer (NSCLC). Although multiple inhibitors have been developed to target diverse EGFR mutations and several have been approved, the inevitable drug resistance and side effect remain a challenge, which motivates novel strategies. Proteolysis-targeting chimeras (PROTACs) have been gaining momentum for their potential as novel therapeutics for human diseases by triggering protein degradation. To date, various potent and specific EGFR PROTACs have been discovered and some of them have entered clinical trials.Areas covered: This review provides an overview of EGFR degraders in patents from 2016 to 2022. It provides an update of the discovery strategies, chemical structures, and molecular profiling of all available EGFR PROTACs. SciFinder, PubMed, Web of Science, EPO, and CNIPA databases were used for searching the literature and patents for EGFR PROTACs.Expert opinion: By employing the PROTAC technology, highly potent and selective EGFR degraders based on four generation EGFR inhibitors have been developed, which offer a new strategy to target EGFR mutations and overcome the drug resistance. Despite the satisfactory result in vitro and in vivo studies, their therapeutic value awaits more rigorous preclinical testing and clinical investigation.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"477-492"},"PeriodicalIF":6.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49689565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An updated patent review of anaplastic lymphoma kinase inhibitors (2018-2022). 间变性淋巴瘤激酶抑制剂的最新专利审查(2018-2022)。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-04-01 DOI: 10.1080/13543776.2023.2216381

Deyi Ma, Mengrao Guo, Xin Zhai

{"title":"An updated patent review of anaplastic lymphoma kinase inhibitors (2018-2022).","authors":"Deyi Ma, Mengrao Guo, Xin Zhai","doi":"10.1080/13543776.2023.2216381","DOIUrl":"https://doi.org/10.1080/13543776.2023.2216381","url":null,"abstract":"Introduction: Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, has emerged as a promising drug target for multiple cancers. Up to now, a total of seven ALK inhibitors have been approved for clinical cancer treatment. However, the issue of resistance to ALK inhibitors was subsequently reported, which led to the exploration of novel generations of ALK inhibitors recently.Areas covered: This paper provides a comprehensive review of the patent literature from 2018 to 2022 about structures, pharmacological data of small molecular ALK inhibitors, and their utilization as anticancer agents. In addition, several potential ALK inhibitors on the market or under clinical investigations are described in detail.Expert opinion: To date, there are no ALK inhibitors that have been approved are completely free of resistance issues, which is a plight needing urgent solution. Development of new ALK inhibitors through structure modification, multi-targeted inhibitors, type-I½ and type-II binding modes, as well as PROTAC and drug conjugates are proceeding. Over the last 5 years, lorlatinib, entrectinib, and ensartinib have been approved, and an increasing number of studies on ALK inhibitors, especially on macrocyclic compounds, have demonstrated their promising therapeutic potency.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":"33 4","pages":"323-337"},"PeriodicalIF":6.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9531091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A patent review of selective CDK9 inhibitors in treating cancer. 选择性CDK9抑制剂治疗癌症的专利回顾。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-04-01 DOI: 10.1080/13543776.2023.2208747

Tizhi Wu, Xiaowei Wu, Yifan Xu, Rui Chen, Jubo Wang, Zhiyu Li, Jinlei Bian

{"title":"A patent review of selective CDK9 inhibitors in treating cancer.","authors":"Tizhi Wu, Xiaowei Wu, Yifan Xu, Rui Chen, Jubo Wang, Zhiyu Li, Jinlei Bian","doi":"10.1080/13543776.2023.2208747","DOIUrl":"https://doi.org/10.1080/13543776.2023.2208747","url":null,"abstract":"Introduction: The dysregulation of CDK9 protein is greatly related to the proliferation and differentiation of various cancers due to its key role in the regulation of RNA transcription. Moreover, CDK9 inhibition can markedly downregulate the anti-apoptotic protein Mcl-1 which is essential for the survival of tumors. Thus, targeting CDK9 is considered to be a promising strategy for antitumor drug development, and the development of selective CDK9 inhibitors has gained increasing attention.Areas covered: This review focuses on the development of selective CDK9 inhibitors reported in patent publications during the period 2020-2022, which were searched from SciFinder and Cortellis Drug Discovery Intelligence.Expert opinion: Given that pan-CDK9 inhibitors may lead to serious side effects due to poor selectivity, the investigation of selective CDK9 inhibitors has attracted widespread attention. CDK9 inhibitors make some advance in treating solid tumors and possess the therapeutic potential in EGFR-mutant lung cancer. CDK9 inhibitors with short half-life and intravenous administration might result in transient target engagement and contribute to a better safety profile in vivo. However, more efforts are urgently needed to accelerate the development of CDK9 inhibitors, including the research on new binding modes between ligand and receptor or new protein binding sites.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":"33 4","pages":"309-322"},"PeriodicalIF":6.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9530086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3